Journal of Alzheimers Disease & Parkinsonism
Open Access

Amyloid plaques are extracellular deposits primarily composed of amyloid beta peptides, which are associated with the pathogenesis of several neurodegenerative disorders, most notably Alzheimer’s Disease (AD). These plaques are among the hallmark features observed in the brains of individuals affected by Alzheimer’s and are widely studied for their role in cognitive decline and neuronal dysfunction. Understanding the formation, structure, and effects of amyloid plaques is crucial for both diagnosis and potential treatment strategies targeting Alzheimer’s disease.

Amyloid plaques form when Aβ peptides, which are fragments derived from the Amyloid Precursor Protein (APP), accumulate and aggregate in the brain. APP is a transmembrane protein found throughout the body but is particularly abundant in the brain. Under normal physiological conditions, APP is cleaved by enzymes called α-secretase and secretase, producing harmless peptide fragments. However, in the amyloidogenic pathway, APP is cleaved by secretase followed by γ-secretase, resulting in the formation of peptides, particularly and the more aggregation-prone Aβ42. These peptides are prone to misfolding and can clump together to form oligomers, fibrils, and eventually mature plaques that deposit in the extracellular spaces of brain tissue.

The aggregation of is a complex process influenced by genetic, environmental, and biochemical factors. Mutations in the genes coding for APP, Presenilin 1 (PSEN1), or Presenilin 2 (PSEN2), all of which are involved in the processing of APP, are known to cause familial early-onset Alzheimer’s disease. These mutations tend to increase the production of Aβ42, the more toxic and aggregation-prone variant, thereby accelerating plaque formation. In sporadic, late-onset Alzheimer’s, genetic risk factors such as the apolipoprotein E (APOE) ε4 allele play a role in modulating Aβ clearance and deposition.

Histologically, amyloid plaques are visible using specific staining techniques, such as Congo red or silver staining, and can be observed under a microscope as dense, fibrous deposits. They are commonly surrounded by dystrophic neurites, activated microglia, and reactive astrocytes, indicating a localized inflammatory response. Two main types of plaques have been described: diffuse plaques, which lack a dense core and are thought to be less toxic, and neuritic or senile plaques, which contain a dense fibrillar core and are more closely associated with neurodegeneration and cognitive impairment [1-5].

The presence of amyloid plaques disrupts the normal architecture and function of brain tissue. While it is still debated whether plaques themselves are the direct cause of neuronal death, there is strong evidence that soluble oligomers, which precede plaque formation, are neurotoxic. These oligomers interfere with synaptic signaling, impair long-term potentiation, and disrupt calcium homeostasis, all of which contribute to cognitive deficits observed in Alzheimer’s disease. Furthermore, the chronic inflammatory response triggered by microglia and astrocytes in the vicinity of plaques may exacerbate neuronal damage through the release of pro-inflammatory cytokines and reactive oxygen species [6-10].

From a diagnostic perspective, amyloid plaques have become a key biomarker for Alzheimer’s disease. Advances in imaging technology, such as Positron Emission Tomography (PET) using radiolabeled tracers that bind to Aβ, allow for in vivo visualization of amyloid deposition in the brain. Additionally, Cerebrospinal Fluid (CSF) analysis can reveal decreased levels of Aβ42, reflecting its deposition in plaques, along with elevated levels of tau proteins, another hallmark of Alzheimer’s pathology.

Amyloid plaques are central to the pathology of Alzheimer’s disease and represent both a challenge and an opportunity in the ongoing quest to understand and treat this devastating condition. While plaques are not the sole contributors to neurodegeneration, their presence reflects a cascade of molecular events leading to synaptic dysfunction and neuronal loss. Continued research into the mechanisms of aggregation, its interactions with neural cells and the development of more effective therapies remains critical in the battle against Alzheimer’s disease and related disorders.

1. Brownell M, Sehar U, Mukherjee U, Reddy PH (2024) Creating Cultural and Lifestyle Awareness about Dementia and Co-morbidities. J Alzheimers Dis Rep 8(1):747-764.

   [Crossref] [Google Scholar] [PubMed]

2. Wortmann M (2012) Dementia: a global health priority-highlights from an ADI and World Health Organization report. Alzheimers Res Ther 4:1-3.

   [Crossref] [Google Scholar] [PubMed]

3. Dugger BN, Dickson DW (2017) Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 9(7):a028035.

   [Crossref] [Google Scholar] [PubMed]

4. Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, et al. (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38(1):171-184.

   [Crossref] [Google Scholar] [PubMed]

5. Silva J, Monge-Fuentes V, Gomes F, Lopes K, dos Anjos L, et al. (2015) Pharmacological alternatives for the treatment of neurodegenerative disorders: Wasp and bee venoms and their components as new neuroactive tools. Toxins 7(8):3179-3209.

   [Crossref] [Google Scholar] [PubMed]

6. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, et al. (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(9):2672-2713.

   [Crossref] [Google Scholar] [PubMed]

7. Goedert M (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci 354(1386):1101-1118.

   [Crossref] [Google Scholar] [PubMed]

8. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, et al. (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58(11):1803-1809.

   [Crossref] [Google Scholar] [PubMed]

9. Frank S (2014) Treatment of Huntington's disease. Neurother 11(1):153-160.

   [Crossref] [Google Scholar]

10. Gibbs Jr CJ, Gajdusek DC, Asher DM, Alpers MP, Beck E, et al. (1968) Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161(3839):388-389.

    [Crossref] [Google Scholar] [PubMed]